ЛАФЕРОБИОН® (interferon alpha 2b recombinant)
Producer: CIAO Biofarm Ukraine
Code of automatic telephone exchange: L03AB01
Release form: Firm dosage forms. Suppositories.
General characteristics. Structure:
Active ingredients: interferon alpha 2b recombinant 150 000 ME, either 500 000 ME, or 1 000 000 ME, or 3 000 000 ME;
excipients: tocopherol acetate, ascorbic acid, solid fat.
Main properties: suppositories of a bullet form, yellow-white color, homogeneous consistence.
Interferon alpha 2b recombinant possesses the expressed anti-virus, anti-proliferative and immunomodulatory action. The complex structure of Laferobiona® causes a number of new effects: in combination with tocopherol acetate and ascorbic acid anti-virus activity of interferon alpha 2b recombinant increases at 10-14 times, its immunomodulatory action on T amplifies - and V-lymphocytes, the content of immunoglobulin E is normalized. The antibodies neutralizing anti-virus activity of interferon alpha 2b recombinant even at its use on an extent of 2 years are not formed, functioning of endogenous system is normalized.
Indications to use:
- at papilomovirusny infections (vulgar warts, sharp-pointed to a condyloma);
- at urogenital a mix infections which are transferred sexually;
- at bacterial, virus and multi-infections;
- at pretumor diseases of a neck of uterus;
In complex therapy different infectious and inflammatory diseases at children, including, newborn and premature:
- at the acute respiratory viral infections (ARVI), pneumonia (bacterial, virus, Chlamidia), meningitis, sepsis, a specific pre-natal infection (clamidiosis, herpes, a cytomegaly, an enteroviral infection, visceral candidiasis, mycoplasmosis);
- for treatment Epstein-Barre of a viral infection at children.
Route of administration and doses:
- at a papilomovirusny infection drug is appointed on 1 500 000 ME 2 times a day with a 12-one-hour break rektalno. Course of treatment of 10 days. Treatment is carried out under control of a cytologic, bacteriological research and manifestations of clinical symptoms;
- at urogenital the mix infections which are transferred sexually and at bacterial virus and multi-infections drug is appointed on 1 000 000 – 1 500 000 ME by 2 times a day with a 12-one-hour break rektalno. Course of treatment of 10 days. Treatment is carried out under control of a cytologic, bacteriological research and manifestations of clinical symptoms. Treatment is carried out both to sexual partners;
- at pretumor diseases of a neck of uterus: on 1 500 000 ME 2 times a day with a 12-chaosvy break rektalno. Course of treatment of 10 days. Further treatment is defined by clinical laboratory indicators.
- in complex therapy of different infectious and inflammatory diseases at children, including newborn and premature, drug is appointed on 150 000 ME on 2 suppositories a day with a 12-hour interval rektalno. Courses of treatment and intervals between courses – for 5 days.
It is recommended quantities of courses:
at a SARS – 1, pneumonia (bacterial – 1-2, virus – 1, Chlamidia – 1), meningitis – 1-2, sepsis – 2-3, at specific pre-natal infections (herpetic – 2, Cytomegaloviral – 2-3, enteroviral – 1-2, mycoplasmosis – 2-3).
To premature novorodzhenny children with gestational age less than 34 weeks 3 times a day (in 8 hours) rektalno appoint drug on 150 000 ME (1 suppository). The course makes 5 days.
- at леченииі Epstein-Barre of a viral infection at children drug is appointed at the rate of 1 million ME to 1 sq.m of the area of a body a day rektalno.
Drug is accepted by 2 times a day with an interval of 12 hours. The course of treatment sostalyat 10 days.
Features of use:
Treatment of Laferobionom® should be carried out under observation of the doctor.
At prolonged use of drug carry out control of the general blood test, functions of a liver, kidneys and a thyroid gland.
After the termination of a period of validity use of drug is inadmissible. Drug is not subject to requality control and extension of a period of validity after its termination.
All side reactions connected using Laferobiona® insignificant or moderately severe. After the end of treatment they, usually disappear.
At introduction of Laferobiona® gripopodobny symptoms are possible: fever, temperature increase, fatigue, slackness, and also headache, muscle, joints pain, perspiration. For weakening of grippopodobny symptoms purpose of paracetamol is recommended.
From a GIT, liver: increase in the ALT and nuclear Heating Plant level, increase in the ShchF level.
From TsNS: at prolonged use dizziness, a sleep disorder are possible.
From cardiovascular system: perhaps arterial hypertension or hypotension; seldom – tachycardia.
- hypersensitivity to recombinant interferon alfa-2 to b or other component of drug;
- diseases of a thyroid gland;
- heavy disturbances of functions of kidneys, liver;
- serious cardiovascular illness;
- epilepsy and other diseases of TsNS (including functional);
- oppression of a myeloid sprout of a hemopoiesis.
In the place protected from light, at a temperature from 2 °C to 8 °C.
According to the recipe
On 150 thousand ME on 5 suppositories in planimetric cell-like packaging, on one planimetric cell-like packaging in a pack.